Generation Bio Co. (NasdaqGM: GBIO)
Health Care · Biotechnology · US
$—
— today · — 1Y
Generation Bio Co. (NasdaqGM: GBIO) operates in the Biotechnology industry within the Health Care sector.
trading between 4.91 and 6.48.
Tweenvest scores Generation Bio Co. across four factors: quality 36/100, value 35/100. Its strongest factor is quality.
GBIO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $15.27M
- P/E
- —
- EPS
- -9.34
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $6.48
- 52-week low
- $4.91
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 115
- Next earnings
- —
About Generation Bio Co.
Generation Bio Co. is a biotechnology firm focused on genetic therapies, working to devise treatments for both uncommon and widespread diseases. The company's current development pipeline includes multiple projects, with a particular emphasis on addressing rare and prevalent conditions affecting the liver and retina. Additionally, it directs its research towards disorders of skeletal muscle, the central nervous system, and oncology. The enterprise, which was initially established as Torus Therapeutics, Inc., adopted its current name, Generation Bio Co., in November 2017. Incorporated in 2016, its main operations are based in Cambridge, Massachusetts.
- ISIN
- US37148K2096
- Founded
- 2016
- Listed since
- Jun 12, 2020
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| PhaseRx, Inc.OTCPK: PZRX.Q | $12.00 | $— | — |
| ContraFect CorporationOTCPK: CFRX.Q | $11.00 | $0.00 | — |
| Notable Labs, Ltd.OTCPK: NTBL.Q | $10.00 | $— | — |
| OncoSec Medical IncorporatedOTCPK: ONCS.Q | $6.00 | $0.00 | — |
| Calithera Biosciences, Inc.OTCPK: CALA | $5.00 | $0.00 | -99.00% |
| Biocept, Inc.OTCPK: BIOC.Q | $3.00 | $0.00 | -99.50% |
| Yield10 Bioscience, Inc.OTCPK: YTEN.Q | $1.00 | $— | — |
| LadRx CorporationOTCPK: LADX | $0.00 | $0.00 | -99.50% |
Figures last refreshed Oct 18, 2026.